Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Extendicare (TSE:EXE) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?

Extendicare logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Extendicare shares moved above their 200‑day moving average (200‑day MA C$23.19), trading as high as C$30.65 and last at C$30.20 on ~147k shares, suggesting a potential technical breakout.
  • Analysts have been upgrading the name — consensus rating is Buy with an average target of C$29.38, and several firms raised targets to roughly C$30–C$34.50 (TD upgraded to Buy with a C$32 target).
  • Key fundamentals: market cap C$2.85B, P/E ~27.1 and debt/equity ~91.9%; last quarter EPS was C$0.29, and the company declared a monthly dividend of C$0.0441 (annual yield ~1.8%, payout ratio ~45%).
  • Five stocks we like better than Extendicare.

Extendicare Inc. (TSE:EXE - Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$23.19 and traded as high as C$30.65. Extendicare shares last traded at C$30.20, with a volume of 146,991 shares changing hands.

Analyst Ratings Changes

EXE has been the topic of a number of research reports. TD Securities upgraded Extendicare from a "hold" rating to a "buy" rating and upped their target price for the company from C$19.00 to C$32.00 in a report on Monday, April 6th. BMO Capital Markets upped their target price on Extendicare from C$24.00 to C$30.00 in a report on Monday, March 2nd. Desjardins set a C$34.50 target price on Extendicare and gave the company a "buy" rating in a report on Wednesday, April 22nd. Canadian Imperial Bank of Commerce upped their target price on Extendicare from C$22.00 to C$32.00 in a report on Thursday, April 2nd. Finally, National Bank Financial upped their target price on Extendicare from C$24.50 to C$29.00 and gave the company an "outperform" rating in a report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to MarketBeat.com, Extendicare currently has a consensus rating of "Buy" and an average target price of C$29.38.

Check Out Our Latest Stock Analysis on Extendicare

Extendicare Stock Down 0.3%

The business has a fifty day moving average of C$27.41 and a 200 day moving average of C$23.19. The stock has a market cap of C$2.85 billion, a price-to-earnings ratio of 27.13 and a beta of 1.27. The company has a debt-to-equity ratio of 91.85, a current ratio of 1.37 and a quick ratio of 0.98.

Extendicare (TSE:EXE - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported C$0.29 EPS for the quarter. Extendicare had a return on equity of 47.65% and a net margin of 5.82%.The firm had revenue of C$462.03 million for the quarter. On average, equities analysts predict that Extendicare Inc. will post 0.6134729 earnings per share for the current year.

Extendicare Dividend Announcement

The company also recently disclosed a monthly dividend, which will be paid on Friday, May 15th. Investors of record on Friday, May 15th will be issued a $0.0441 dividend. The ex-dividend date is Thursday, April 30th. This represents a c) dividend on an annualized basis and a yield of 1.8%. Extendicare's dividend payout ratio is currently 44.92%.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines